By SPC Staff
The FDA expanded the approval for fibrinogen (human) lyophilized powder for reconstitution (Fibryga, Octapharma) to include fibrinogen replacement in bleeding patients with acquired fibrinogen deficiency (AFD).
Fibryga was previously approved for acute bleeding episodes in adults and children with congenital fibrinogen deficiency.
The current standard of care for AFD is cryoprecipitate, which has drawbacks that include lengthy thawing and preparation processes and heightened